China, Ja­pan grant patents to Galectin Ther­a­peu­tics

BioSpectrum (Asia) - - Regulatory News -

Galectin Ther­a­peu­tics, Inc., the lead­ing de­vel­oper of ther­a­peu­tics that tar­get galectin pro­teins to treat non-al­co­holic steato­hep­ati­tis (NASH) cir­rho­sis and can­cer, has re­ceived two new patents in China and two new patents in Ja­pan for the com­pany’s lead com­pound, GR-MD-02. It is a car­bo­hy­drate-based drug that in­hibits the galectin-3 pro­tein that is di­rectly in­volved in mul­ti­ple in­flam­ma­tory, fi­brotic, and ma­lig­nant dis­eases.

The two patents from China pro­vide broad in­tel­lec­tual prop­erty cov­er­age. The first patent cov­ers GR-MD-02 com­po­si­tion of mat­ter and meth­ods of use broadly for the treat­ment of fi­bro­sis, in­flam­ma­tory and au­toim­mune dis­or­ders, or can­cer. The sec­ond patent ex­tends the use of GR-MD-02 to a va­ri­ety of other dis­eases in­clud­ing neu­rode­gen­er­a­tive dis­ease, pso­ri­a­sis, cu­ta­neous and sys­temic lu­pus ery­the­mato­sus, sys­temic scle­ro­sis (scle­ro­derma) and der­mati­tis.

The two new Ja­panese patents, in com­bi­na­tion with the com­pany’s two ex­ist­ing Ja­panese patents, pro­vide broad in­tel­lec­tual prop­erty cov­er­age in­clud­ing GR-MD-02 com­po­si­tion of mat­ter and all po­ten­tial ther­a­peu­tic in­di­ca­tions un­der de­vel­op­ment in this im­por­tant phar­ma­ceu­ti­cal mar­ket.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.